Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Koch, Raphael, Christie, Amanda L., Crombie, Jennifer L., Palmer, Adam C., Plana, Deborah, Shigemori, Kay, Morrow, Sara N., Van Scoyk, Alexandria, Wu, Wenchao, Brem, Elizabeth A., Secrist, J. Paul, Drew, Lisa, Schuller, Alwin G., Cidado, Justin, Letai, Anthony, Weinstock, David M.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2019
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367646/
https://ncbi.nlm.nih.gov/pubmed/30498064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-865527
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki